Investment
Schering-Plough has announced it is to invest $60 million in early drug discovery technologies across three of its worldwide locations in Scotland, US and the Netherlands.
Half of the investment is to be spent at the Newhouse facility in Scotland, acquired when it bought Organon Biosciences in November 2007. Ismail Kola, Chief Scientific Officer, said, “The company has a long-term commitment to its research activities in Scotland and recognises the important contribution our colleagues make.” The Newhouse facility will specialise in central nervous system research, with a focus on analgesia and psychiatry, and will also do research in cardiovascular and metabolic diseases.
Schering Plough had the inducement of a £4.1 million grant from the Scottish government.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.